From GlobeNewswire: 2024-04-04 09:00:00

The global hepatology market is projected to grow from USD 14.57 billion in 2023 to USD 43.65 billion by 2033, with a CAGR of 11.60%. Key players are heavily investing in R&D to develop new treatments for liver-related diseases such as hepatitis, liver cirrhosis, fatty liver disease, and liver cancer. Antiviral drugs are expected to dominate the market, targeting conditions like hepatitis and liver cancer. North America and Asia-Pacific are key regions driving growth in the hepatology market. Recent developments include key findings from Takeda and Arrowhead Pharmaceuticals Inc. on the efficacy of investigational Fazirsiran in treating liver disease caused by alpha-1 antitrypsin deficiency. The market is segmented by treatment type and disease type, with a focus on antiviral drugs for hepatitis and liver cancer. Ongoing research initiatives and advancements in medical technology are propelling the global hepatology market forward.



Read more at GlobeNewswire: Global Hepatology Market Size To Worth USD 43.65 Billion By